Figure 7.

Protective effects of LMW-H/P NPs on bioactivity of trypsin-treated FGF-2. Stock solutions (10 μg/mL FGF-2 with 3.14 mg/mL LMW-H/P NPs with 20 mg/mL dextran (•), 1.6 mg/mL LMW-H with 20 mg/mL dextran (Δ), 20 mg/mL dextran alone (□) or control (non) (○)) were treated with trypsin at 37°C for the indicated periods of time. After trypsinization, proteolysis was stopped by adding FBS, and inactivated FGF-2 in the stock solutions was diluted to 10 ng/mL with culture medium. HMVECs were cultured for 3 days using one of the prepared media, and data represent means ± SD of quadruplicate determinations.

Abbreviations: FGF-2, fibroblast growth factor-2; HMVECs, human dermal micro-vascular endothelial cells; LMW-H, low-molecular-weight heparin; LMW-H/P, low-molecular-weight heparin/protamine; NP(s), nanoparticle(s); SD, standard deviation.